Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-α). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, newonset psoriasis in a patient on infliximab for rheumatoid arthritis.
|Original language||English (US)|
|Journal||Dermatology online journal|
|State||Published - Sep 2008|
ASJC Scopus subject areas